Form 4: Macrogenics Director O'Brien Acquires Stock Options and Restricted Stock Units

Director Federica F. O'Brien reports acquisition of stock options and restricted stock units in Macrogenics Inc.

Summary

• Federica F. O'Brien, a director of Macrogenics Inc. (MGNX), filed a Form 4 disclosing changes in beneficial ownership.
• On May 21, 2024, O'Brien acquired 6,500 Restricted Stock Units (RSUs) and 16,500 stock options.
• The RSUs vest one year after the grant date or the day before the next annual meeting, whichever is earlier.
• The stock options vest in monthly increments over 12 months from the grant date and expire on May 21, 2034.
• The exercise price of the stock options is $4.26.
• Following the reported transactions, O'Brien directly owns 6,500 RSUs and 16,500 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSU grants, which are common compensation practices. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard corporate governance.

Positives

• The acquisition of stock options and RSUs by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules (one year for RSUs, monthly over 12 months for options) are fairly standard in the industry.
• Comparable companies like Amgen, Gilead, and Biogen also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• The acquisition of stock options and RSUs by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates